← Open Payments lookup

CLEMENT EFOBI: Open Payments

NPI 1952943037 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$718 in 34 payments from 10 companies in 2025. Trend: 2023 $390 · 2024 $165 · 2025 $718

Food & beverage: $718
CompanyPaymentsAmount
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)10$229
Supernus Pharmaceuticals, Inc.8$140
Otsuka America Pharmaceutical, Inc.5$117
E.R. Squibb & Sons, L.L.C.3$75
ABBVIE INC.2$41
Axsome Therapeutics, Inc.2$35
Novo Nordisk Inc1$33
Teva Pharmaceuticals USA, Inc.1$18
TMS NeuroHealth Centers Inc.1$16
Alkermes, Inc.1$14

Products named: CAPLYTA, Qelbree, COBENFY, ABILIFY ASIMTUFII, REXULTI, VRAYLAR, Auvelity, ABILIFY MAINTENA.

Industry payments across DC — which companies pay providers there.